Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. 31504139

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%). 29219616

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE The use of immunohistological staining to detect the level of expression of the c-erbB-2 protein in human breast adenocarcinomas may be of value in predicting tumour behaviour. 2885574

1987

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Trastuzumab® is used for human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. 29277796

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE HER-2/neu immunopositivity was more prevalent in adenocarcinomas than in LMP tumors, and the proportion of HER-2/neu-positive adenocarcinomas increased with the progression of the disease. 9398993

1997

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE None of 40 patients with proximal lesions had overexpression of HER-2/neu, whereas four of 40 (10%) distal adenocarcinomas had a 16-24-fold gene amplification (P = 0.04). 7851555

1995

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE The overexpression of HER2 is among those changes and is often detected in adenocarcinomas such as breast, ovarian, lung, and gastric cancer. 10950153

2000

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Human epidermal growth factor receptor 2 (HER2) is expressed in some gastric and gastroesophageal junction adenocarcinomas. 30624589

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE EGFR and HER2 proteins were expressed in 23 and 17 of 55 adenocarcinomas with MX. 16189154

2005

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Only 2 AVCs (7.7%; both intestinal-type) showed a HER2 overexpression (both 2+), which corresponded to a HER2 gene amplification at CISH analysis. 29731265

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. 3345525

1988

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE The median age was 60.1 ± 14.5 (standard deviation) years; 89% (n = 106/119) had performance status 0/1 at diagnosis; 79% (n = 103/130) were non- or former smokers; 93% (n = 120/129) had adenocarcinomas and 74%(n = 97)/19%(n = 25)/7%(n = 10) had disease stages IV/III/I-II at diagnosis, respectively; co-mutations included EGFR (n = 2), BRAF (n  = 2), KRAS (n = 1), and HER2 (n = 1). 28762087

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression LHGDN Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma. 14607699

2002

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE This study aimed to investigate the role and relationship of Her2 and HSP90 in gastric and gastro-esophageal adenocarcinomas. 23874879

2013

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE HER2 S310Y single site substitution was discovered in recent years and afatinib efficacy for adenocarcinoma patients harboring S310Y mutation has not been reported. 29561699

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE In cervical adenocarcinomas, expression of c-myc was seen in 5 of 7 cases (71.6%), EGFR in all cases and c-erbB-2 in 2 of 7 cases (28.6%). c-myc immunoactivity was observed as nuclear or cytoplasmic stain or both, EGFR as membrane and cytoplasmic stain, c-erbB-2 as membrane stain. 1687493

1991

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE HER-2 negativity may represent a predictor of pathologic response to neoadjuvant chemotherapy for gastric and oesophago-gastric junction adenocarcinoma. 28276033

2017

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Of the 34 cases, three well differentiated adenocarcinomas had extremely high levels of p185ERBB2. 1979253

1990

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE In this study, we conducted immunohistochemical analysis and fluorescence in situ hybridization (FISH) for HER2 on 49 primary nonampullar small intestinal adenocarcinomas. 21088150

2010

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression LHGDN Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. 14744769

2004

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE The postoperative 5-year survival rate of patients with adenocarcinoma according to the expression of HER2 scores 0, 1, 2 and 3 was 75.3%, 77.8%, 76.5% and 20.0%, respectively. 22199341

2011

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Hepatoid adenocarcinomas showed relatively frequent expressions of HER2 (score 3+/2+: 21%/19%). 30946937

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression LHGDN Expression levels of p21(WAF1/CIP1) and HER-2/neu were examined imunohistochemically and the amplification of HER-2/neu gene was evaluated by fluorescence in situ hybridisation in HER-2/neu overexpressing adenocarcinomas. 15190415

2004

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Overexpression of the HER2 (neu/c-erbB-2) oncogene frequently coincides with an aggressive clinical course of certain human adenocarcinomas. 11360194

2001

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. 30825613

2019